MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ
11.77
-0.62
-4.97%
Opening 14:00 03/27 EDT
OPEN
12.13
PREV CLOSE
12.38
HIGH
12.74
LOW
11.77
VOLUME
560.68K
TURNOVER
--
52 WEEK HIGH
14.93
52 WEEK LOW
3.895
MARKET CAP
1.18B
P/E (TTM)
-7.9779
1D
5D
1M
3M
1Y
5Y
1D
ORIC Pharmaceuticals To Share Combination Dose Optimization Data From Phase 1b Study Of Rinzimetostat In Participants With Metastatic Castration Resistant Prostate Cancer
Benzinga · 5h ago
Oric Pharmaceuticals to present Phase 1b rinzimetostat combination dose-optimization data in mCRPC; March 31 conference call set for 4:30pm ET
Reuters · 5h ago
ORIC® PHARMACEUTICALS TO REPORT COMBINATION DOSE OPTIMIZATION DATA FROM PHASE 1B TRIAL OF RINZIMETOSTAT IN PATIENTS WITH MCRPC
Reuters · 5h ago
Weekly Report: what happened at ORIC last week (0316-0320)?
Weekly Report · 4d ago
Oric Pharmaceuticals to present rinzimetostat preclinical data at AACR Annual Meeting
Reuters · 03/17 21:01
ORIC® PHARMACEUTICALS ANNOUNCES PRECLINICAL RINZIMETOSTAT (ORIC-944) PRESENTATIONS AT THE 2026 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
Reuters · 03/17 21:01
Weekly Report: what happened at ORIC last week (0309-0313)?
Weekly Report · 03/16 09:06
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support
Simply Wall St · 03/15 13:24
More
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Webull offers ORIC Pharmaceuticals Inc stock information, including NASDAQ: ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.